Umesh C Sharma1, Wassim Mosleh2, Milind R Chaudhari2, Rujuta Katkar2, Brian Weil2, Chris Evelo3, Thomas R Cimato2, Saraswati Pokharel4, W Matthijs Blankesteijn5, Gen Suzuki2. 1. Division of Cardiovascular Medicine, University at Buffalo, Buffalo, NY, USA. Electronic address: sharmau@buffalo.edu. 2. Division of Cardiovascular Medicine, University at Buffalo, Buffalo, NY, USA. 3. Department of Bioinformatics-BiGCaT, University of Maastricht, Maastricht, The Netherlands. 4. Department of Pathology and Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA. 5. Department of Pharmacology, University of Maastricht, Maastricht, The Netherlands.
Abstract
BACKGROUND: Acute myocardial infarction (MI) causes significant changes in cardiac morphology and function. Galectin-3 is a novel and potentially therapeutically important mediator of cardiac remodelling. Myocardial and serum galectin-3 expression dynamics in response to the early cardiovascular outcomes after acute MI are not fully elucidated. METHODS: We first performed a comprehensive longitudinal microarray analyses in mice after acute MI. We then measured the serum levels of galectin-3 in a translational porcine model of coronary microembolism-induced post-ischaemic cardiac remodelling. We validated our pre-clinical studies in humans by measuring serum galectin-3 levels of 52 patients with acute ST-elevation MI (STEMI) and 11 healthy controls. We analysed galectin-3 data in relation to the development of major adverse cardiovascular outcomes (MACO). RESULTS: Of the 9,753 genes profiled at infarcted and remote myocardium at eight different time points, dynamic myocardial overexpression of galectin-3 mRNA was detected. In a pig model of diffuse myocardial damage and cardiac remodelling, galectin-3 localised to the areas of tissue damage and myocardial fibrosis, with proportionate increase of their serum galectin-3 expression levels. In humans, increased serum galectin-3 level was associated with in-hospital MACO. CONCLUSIONS: In this translational study, we demonstrated that galectin-3 is dynamically overexpressed in response to acute MI-induced cardiac remodelling. Elevated galectin-3 levels are associated with the development of in-hospital MACO.
BACKGROUND:Acute myocardial infarction (MI) causes significant changes in cardiac morphology and function. Galectin-3 is a novel and potentially therapeutically important mediator of cardiac remodelling. Myocardial and serum galectin-3 expression dynamics in response to the early cardiovascular outcomes after acute MI are not fully elucidated. METHODS: We first performed a comprehensive longitudinal microarray analyses in mice after acute MI. We then measured the serum levels of galectin-3 in a translational porcine model of coronary microembolism-induced post-ischaemic cardiac remodelling. We validated our pre-clinical studies in humans by measuring serum galectin-3 levels of 52 patients with acute ST-elevation MI (STEMI) and 11 healthy controls. We analysed galectin-3 data in relation to the development of major adverse cardiovascular outcomes (MACO). RESULTS: Of the 9,753 genes profiled at infarcted and remote myocardium at eight different time points, dynamic myocardial overexpression of galectin-3 mRNA was detected. In a pig model of diffuse myocardial damage and cardiac remodelling, galectin-3 localised to the areas of tissue damage and myocardial fibrosis, with proportionate increase of their serum galectin-3 expression levels. In humans, increased serum galectin-3 level was associated with in-hospital MACO. CONCLUSIONS: In this translational study, we demonstrated that galectin-3 is dynamically overexpressed in response to acute MI-induced cardiac remodelling. Elevated galectin-3 levels are associated with the development of in-hospital MACO.
Authors: Ravi V Shah; Annabel A Chen-Tournoux; Michael H Picard; Roland R J van Kimmenade; James L Januzzi Journal: Eur J Heart Fail Date: 2010-06-05 Impact factor: 15.534
Authors: Giuseppe Maiolino; Giacomo Rossitto; Luigi Pedon; Maurizio Cesari; Anna Chiara Frigo; Matteo Azzolini; Mario Plebani; Gian Paolo Rossi Journal: Arterioscler Thromb Vasc Biol Date: 2015-01-22 Impact factor: 8.311
Authors: Blanche Schroen; Stephane Heymans; Umesh Sharma; W Matthijs Blankesteijn; Saraswati Pokharel; Jack P M Cleutjens; J Gordon Porter; Chris T A Evelo; Rudy Duisters; Rick E W van Leeuwen; Ben J A Janssen; Jacques J M Debets; Jos F M Smits; Mat J A P Daemen; Harry J G M Crijns; Paul Bornstein; Yigal M Pinto Journal: Circ Res Date: 2004-07-29 Impact factor: 17.367
Authors: Jay S Shavadia; Wendimagegn Alemayehu; Christopher deFilippi; Cynthia M Westerhout; Jasper Tromp; Christopher B Granger; Paul W Armstrong; Sean van Diepen Journal: J Thromb Thrombolysis Date: 2021-10-27 Impact factor: 2.300
Authors: Olivera M Andrejic; Rada M Vucic; Milan Pavlovic; Lana McClements; Dragana Stokanovic; Tatjana Jevtovic-Stoimenov; Valentina N Nikolic Journal: Sci Rep Date: 2019-09-11 Impact factor: 4.379